Stemline Therapeutics, Inc.

Cancer Stem Cells (CSCs) comprise a unique subpopulation of neoplastic cells within tumors that is highly tumorigenic and relatively resistant to standard therapy.

Importantly, while conventional anti-cancer treatments (e.g. chemotherapy and radiation) can often transiently shrink tumors by targeting tumor bulk, these therapies fail to target and kill CSCs leading to treatment failure, relapse, and ultimately death.

Accordingly, in order to overcome these traditional pitfalls, Stemline is developing novel therapeutics that target and eradicate CSCs.